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Pulmonary complications in patients with hematological malignancies are often caused by infection but are
sometimes associated with an underlying disease such as organizing pneumonia (OP). Here, we report a case of
life-threatening steroid-resistant OP associated with myelodysplastic syndrome (MDS) and successfully performed
allogeneic hematopoietic cell transplantation (HSCT). A 33-year-old female with refractory anemia with excess
blasts-1 that had progressed from refractory anemia with ringed sideroblasts and concomitant Sweet’s syndrome
was admitted. Multiple pulmonary infiltrates were revealed on a chest computed tomography scan, which progressively
worsened even after chemotherapy and corticosteroid therapy. No evidence of infection was observed in
bronchoalveolar lavage fluid. A histological examination of a transbronchial lung biopsy specimen showed lymphocyte
invasion with fibrosis, indicating that the pulmonary infiltrates were OP associated with MDS. Before transplantation,
she suffered from respiratory failure and required oxygen supplementation. She developed idiopathic pneumonitis
syndrome on day 61 that responded well to corticosteroid therapy, and the OP pulmonary infiltrates improved
gradually after HSCT, She was discharged on day 104 and is well without recurrence of OP or MDS 2 years after HSCT.
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Pulmonary complications in patients with hematologic
malignancies are due mainly to infections from their
neutropenic status. However, pulmonary complications
are occasionally associated with underlying malignant
diseases, including leukemic cell infiltration, Sweet’s
syndrome, organizing pneumonia (OP), or pulmonary
alveolar proteinosis. OP associated with hematologic
disorders has been reported in patients with acute
leukemia, Non-Hodgkin’s lymphoma, and myelodys-
plastic syndrome (MDS) (Cordier 2000), although the
frequency is quite rare. Daniels et al. reported that there* Correspondence: nfujii@md.okayama-u.ac.jp
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(Daniels et al. 2007). They also reported that OP in
patients with these hematologic diseases responds
favorably to corticosteroid therapy, however, treatment
of underlying disease is needed for patients with
steroid-refractory OP.
Here, we report a case of life-threatening steroid-
resistant OP associated with MDS that was also refractory
to chemotherapy. We successfully performed allogeneic
hematopoietic cell transplantation (HSCT).Case report
A 33-year-old female was admitted to our hospital with
high fever, general fatigue, and rapidly worsening systemic
erythemic nodules with pustules (Figure 1A). She had a
10-year history of MDS, refractory anemia with ringedn Open Access article distributed under the terms of the Creative Commons






Figure 1 Clinical and histopathological presentation. A. Erythemic nodules with pustules on the right upper arm. B. Hematoxylin-eosin stain
of the erythemic nodules: Dense dermal neutrophilic infiltrates with edema. Necrotizing vasculitis is not observed. C. May–Giemsa stain of the
bone marrow. (×1,000). D. Iron stain of a bone marrow smear. Ringed sideroblasts constituted 85% of erythroid precursors. (×1,000). E.
Hematoxylin-eosin stain of transbronchial lung biopsy material. Lymphocyte invasion accompanied with fibrosis was observed. (×100).
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however, no systemic chemotherapy for MDS had been
administered in other hospital. She had been treated only
with intermittent topical and oral corticosteroid therapy
for Sweet’s syndrome. On admission, a complete blood
count examination revealed mild leukocytosis and anemia
(white blood cells, 8.79 × 109 cells/L; hemoglobin, 8.1 g/dl;
hematocrit, 25.8%; red blood cells, 2.77 × 1012 cells/L;
platelets, 15.3 × 109 platelets/L). Peripheral blood smears
showed that 32.5% of the cells were erythroblasts with
a marked left-shift in neutrophils (myeloblasts, 3.5%;
myelocytes, 4%; metamyelocytes, 1.5%; bands, 22%; seg-
ments, 29%) with 1.0% eosinophils, 2.5% basophils, and
36.5% lymphocytes. A bone marrow examination revealedhypercellularity with 62.3% erythropoietic cells, 23.6%
granulopoietic cells, and 2.3% blasts (Figure 1C). Ringed
sideroblasts constituted 85% of the erythroid precursors
(Figure 1D). A cytogenetic analysis revealed 46, XX, +1,
der (1;7)(q10; p10) and del (20)(q11.2q13.3). A skin biopsy
reconfirmed dense dermal neutrophilic infiltrates with
edema without necrotizing vasculitis in hematoxylin-
eosin-stained sections (Figure 1B). A diagnosis of refrac-
tory anemia with excess blasts-1 that had progressed from
RARS with concurrent Sweet’s syndrome was made. A
chest computed tomography (CT) scan on admission
revealed multiple bilateral nodules suspicious of a fungal
infection (Figure 2A). Although tests based on several
techniques for detecting a fungal infection, including
A B
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Figure 2 Chest computed tomography scan. A. Scan on admission. B. Scan during chemotherapy (on day-28 before allogeneic transplantation).
C. Scan on day +61 after allogeneic transplantation. D. Scan on day +195 after allogeneic transplantation.
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and cultures of various tissues were negative, we started
voriconazole and broad-spectrum antibiotics.
She was treated with a single course of combination
chemotherapy consisting of aclarubicin, Ara-C, granulo-
cyte colony-stimulating factor, and two courses of azaciti-
dine. The effects of the chemotherapy were considerably
limited and her clinical symptoms, including high fever
and skin nodules, did not improve. Additionally, her
pulmonary infiltrates progressively worsened during
chemotherapy (Figure 2B). Methylprednisone (mPSL)
pulse therapy was administered; however, the pulmonary
infiltrate condition did not improve. Fiber-optic bron-
choscopy and a bronchoalveolar lavage (BAL) were
performed to characterize the pulmonary infiltrates.
The BAL fluid included 19 × 104 cells consisting of
lymphocytes (77%), macrophages (23%), and few or no
neutrophils (0%). A lymphocyte subset demonstrated
that 83.2% of the lymphocytes were CD3+ T cells and
the ratio of CD4+: CD8+ T cells was 0.65. No bacteria
or fungi were seen on Gram-stained preparations or in
BAL fluid cultures. A histological examination of ma-
terial obtained by transbronchial lung biopsy (TBLB)
showed lymphocyte invasion accompanied by some
fibrosis (Figure 1E).
Therefore, it was likely that the pulmonary infiltrates
were OP associated with MDS; thus, she received an
allogeneic peripheral blood stem cell transplant (PBSCT).
The donor was human leukocyte antigen (HLA)-A
serological and HLA-A and B allele mismatched motherbecause she had no alternative donor source. The pre-
parative regimen consisted of fludarabine (30 mg/m2) for
5 days and busulfan (3.2 mg/m2) for 2 days. Graft-
versus-host disease prophylaxis was initiated with tacroli-
mus and short-term methotrexate. The tacrolimus was
changed to cyclosporine A on day 57 due to renal dys-
function. Prefrozen peripheral blood stem cells contained
4.4 × 106 cells/kg CD34+ cells were administered. The
absolute neutrophil count recovered to 0.5 × 109 neu-
trophils/L on day 15 and the platelet count reached
50 × 109 platelets/L on day 17. Using the short tandem
repeat-polymerase chain reaction method, we confirmed
that the chimerism of peripheral blood CD3+ T lympho-
cytes was complete (100%) donor type on day 20. A
bone marrow examination was performed on day 34, and
cytogenetic remission was confirmed by fluorescence in situ
hybridization. Although pulmonary infiltrates on chest X-
ray improved gradually, she complained of respiratory
distress on day 61 (Figure 2C). A chest CT scan indicated
ground-glass opacity, and an arterial blood gas (ABG)
analysis indicated carbon dioxide narcosis; thus, she
required short-term (10 days) mechanical ventilation.
Fiberoptic bronchoscopy was performed, and her BAL
fluid included macrophages and lymphocytes. No bacteria
or fungi were seen on Gram-stained preparations or in
BAL fluid cultures. We concluded that the etiology of the
pulmonary distress was idiopathic pneumonitis syndrome.
The patient received three doses of 250-mg mPSL
mini-pulse therapy and the ABG and chest X-rays of
the pulmonary infiltrates improved remarkably. On day
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plementation, and a chest CT scan on day 12 of mPSL
administration revealed a remarkable improvement in
ground-glass opacity. Finally, she was discharged on
day 104 after HSCT. A bone marrow examination on
day 153 after HSCT demonstrated complete remission
of the MDS, and no Sweet’s syndrome was observed. A
follow-up chest CT scan on day 195 (Figure 2D) revealed
that no pulmonary infiltrates or ground-glass opacity had
recurred. She is currently well without recurrence of OP
or MDS 2 years after HSCT.
Discussion
Pulmonary complications in patients with hematological
malignancies are most often caused by bacterial or fun-
gal infections; therefore, we treat patients with broad
spectrum antibiotics and/or antifungal agents as first-line
treatment (Wingard et al. 2012). In addition, patients
can occasionally suffer from heart failure or pulmonary
hemorrhage due to cytopenia or the effects of anticancer
drugs. Nevertheless, previous reports have demonstrated
that pulmonary infiltration can be associated with an
underlying disease, including leukemic cell infiltration,
Sweet’s syndrome, pulmonary alveolar proteinosis, or
OP (Tenholder et al. 1990; Stemmelin et al. 1991; Drent
et al. 1997; Daniels et al. 2007). A TBLB and BAL are the
most useful methods for diagnosing such conditions,
including leukemic cell infiltration or pulmonary alveolar
proteinosis. However, the differential diagnosis of Sweet’s
syndrome and OP is difficult.
Basically, the pathological difference between pulmonary
Sweet’s syndrome and OP is clarified by the invaded
cell types. Sweet’s syndrome of the lung usually shows
interstitial edema with alveolar exudate of the neutrophils
(Takimoto et al. 1991). On the other hand, increased
lymphocytes with other cells including neutrophils,
eosinophils, plasma cells,or mast cells are seen in OP
(Cordier 2000). Diagnosis is further confirmed if buds
of granulation tissue were detected (Reid et al. 1996).
Unfortunately, buds of granulation tissue were not identi-
fied in the TBLB sample. However, BALF findings strongly
indicated that our case was OP.
The first-line treatment for OP associated with MDS is
corticosteroid therapy (Cordier 2000; Daniels et al. 2007).
Many reports have suggested the efficacy of corticoste-
roids; however, the pulmonary infiltration in our patient
was refractory to corticosteroids, and severe respiratory
distress was observed. Additionally, the status of MDS
had progressed. Based on these findings, we performed
allogeneic PBSCT to treat both the MDS and MDS-related
OP. It is possible that her OP responded to calcineurin
inhibitors because immunosuppressive drugs are one of
the alternative treatment against OP (Cordier 2000).
Lee et al. reported that cyclosporine with macrolide wereused for the treatment of steroid-refractory OP (Lee et al.
2011). Further study about treatment strategies for steroid-
refractory OP is warranted.
Problems with allogeneic HSCT for patients with
pulmonary complications include transplant-related mor-
tality. Pulmonary comorbidities are the most prevalent
in the hematopoietic cell transplantation (HCT)-specific
comorbidity index (HCT-CI), (Sorror et al. 2005). The
patient’s respiratory status, complaints of dyspnea at rest,
and requirement for O2 at the time of transplantation
indicated severe pulmonary comorbidity that merited
the highest score. The presence of pulmonary disease
in MDS patients is an independent prognostic factor in
a univariate analysis and HCT-CI is prognostic impact-
independent of the International Prognostic Scoring
System (Zipperer et al. 2009). In contrast, Tabata et al.
reported successful allogeneic HSCT for a patient with
MDS and severe pulmonary alveolar proteinosis. Although
it was difficult to decide to perform allogeneic HSCT for
our patient, we successfully performed the procedure in a
patient with MDS and severe pulmonary complications.
In conclusion, allogeneic HSCT should be considered a
treatment option if pulmonary complications are definitely
associated with an underlying hematological malignancy.
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